Gan & Lee Pharmaceuticals Co Ltd

Price Chart

Risk-Adjusted Performance

Gan & Lee Pharmaceuticals Co Ltd (603087) Price Performance

Gan & Lee Pharmaceuticals Co Ltd (603087) trades on SHG in CNY. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at CNY57.44, down 3.70% from the previous close.

Over the past year, 603087 has traded between a low of CNY41.50 and a high of CNY79.62. The stock has gained 27.5% over this period. It is currently 27.9% below its 52-week high.

Gan & Lee Pharmaceuticals Co Ltd has a market capitalization of $37.28B, with a price-to-earnings ratio of 39.75 and a dividend yield of 1.60%.

About Gan & Lee Pharmaceuticals Co Ltd

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and other medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.